ZBIO Share Price Performance
US$26.54
7.78 (41.47%)
Price US$26.54
Share PriceUS$26.54
Zenas BioPharma, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
ZBIO Community Narratives
There are no narratives available yet.
Recent ZBIO News & Updates
Zenas BioPharma, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -4.20
- Gross Margin
- -970.86%
- Net Profit Margin
- -1,180.05%
- Debt/Equity Ratio
- 0%
Zenas BioPharma, Inc. Competitors
Snowflake Analysis
About ZBIO
- Founded
- 2019
- Employees
- 130
- CEO
- WebsiteView website
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
U.S. Market Performance
- 7 Days: -1.3%
- 3 Months: 7.3%
- 1 Year: 14.4%
- Year to Date: 13.5%
Over the last 7 days, the market has dropped 1.3%, driven by a pullback of 2.1% in the Financials sector. In contrast to the last week, the market is actually up 14% over the past year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›